Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal versus intravenous ketamine for major depressive disorder
IRCT20250213064716N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Started Feb 2025; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20250213064716N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250213064716N1.